Hemostemix Inc.
HMTXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.41 | 0.04 | 0.07 | 0.03 |
| FCF Yield | -19.22% | -26.23% | -49.53% | -39.59% |
| EV / EBITDA | -7.14 | -4.11 | -4.98 | -3.63 |
| Quality | ||||
| ROIC | 111.15% | 91.03% | 167.38% | 168.47% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.57 | 1.17 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -33.98% | 76.73% | -75.46% | 41.80% |
| Safety | ||||
| Net Debt / EBITDA | -2.14 | -1.79 | -1.22 | -0.46 |
| Interest Coverage | -3.17 | 0.00 | -9.34 | -635.64 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.00 |
| Cash Conversion Cycle | 0.00 | -4,291,023.48 | -1,930,897.19 | -1,211,318.64 |